Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28474319 | 0.84 | TSHR (0.70) | TSHRMAPTALDH1A1KMT2AHPGD | |
| Trifluoroacetic Acid SCHEMBL9333894 | 0.83 | TSHR (0.61) | TSHRMAPTKMT2AMEN1HTT | |
| Trifluoroacetic Acid SCHEMBL584478 | 0.83 | TSHR (0.61) | TSHRMAPTKMT2AMEN1HTT | |
| Hydrochloric Acid SCHEMBL11292438 | 0.82 | TSHR (0.67) | TSHRMAPTALDH1A1KMT2AHPGD | |
| Acetone SCHEMBL27782568 | 0.81 | TSHR (0.74) | TSHRMAPTALDH1A1KMT2AMEN1 | |
| Acetic Acid SCHEMBL3959213 | 0.81 | TSHR (0.74) | TSHRMAPTALDH1A1KMT2AMEN1 | |
| Bicarbonate SCHEMBL28202106 | 0.81 | TSHR (0.74) | TSHRMAPTALDH1A1KMT2AHPGD | |
| SCHEMBL11220257 | 0.81 | TSHR (0.93) | TSHRMAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL27990562 | 0.81 | — | — | |
| Carbamic Acid SCHEMBL28078506 | 0.79 | TSHR (0.70) | TSHRMAPTALDH1A1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579459-B2 | Activator bound solid supports for nucleic acid synthesis via the phosphoramidite approach | NGO NAM Q | 2009-08-25 | — | — | US | disclosed |
| US-20070135626-A1 | Activator bound solid supports for nucleic acid synthesis via the phosphoramidite approach | CTGEN, INC (US) | 2007-06-14 | — | — | US | disclosed |
| US-6809195-B1 | COMPRISES A MODIFIED PHOSPHORAMIDITE PROTOCOL IN WHICH OXIDATION AND CAPPING STEPS ARE COMBINED INTO A SINGLE STEP; INCREASED EFFICIENCY; SOLID PHASE SYNTHESIS | ISIS PHARMACEUTICALS, INC. | 2004-10-26 | — | — | US | disclosed |
| US-20040198972-A1 | Processes for the preparation of oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2004-10-07 | — | — | US | disclosed |
| US-6762281-B2 | GENERATING PREFERENTIAL OLIGOMERS; GENERATE OLIGOMER, DEPROTECT, EXPOSE TO PHOSPHOROUS, OXIDIZE, EXPOSE TO SULFUR, CLEAVE, RECOVER PRODUCT | ISIS PHARMACEUTICALS, INC. | 2004-07-13 | — | — | US | disclosed |
| EP-1311526-A1 | PROCESSES FOR THE PREPARATION OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2003-05-21 | — | — | EP | disclosed |
| US-6559279-B1 | Generation of peptide linked oligomers; generate solid support, expose to deprotecting agent, incubate with nucleoside, cap, cleave and recover peptide derivative | ISIS PHARMACEUTICALS, INC. | 2003-05-06 | — | — | US | disclosed |
| US-20020156235-A1 | Process for preparing peptide derivatized oligomeric compounds | IONIS PHARMACEUTICALS, INC. | 2002-10-24 | — | — | US | disclosed |
| WO-2002014340-A1 | PROCESSES FOR THE PREPARATION OF OLIGONUCLEOTIDES_______________ | ISIS PHARMACEUTICALS, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
| US-5574146-A | Oligonucleotide synthesis with substituted aryl carboxylic acids as activators | BECKMAN INSTRUMENTS, INC. (US) | 1996-11-12 | — | — | US | disclosed |
| EP-0725787-A1 | ACTIVATED NUCLEOSIDE PHOSPHORAMIDITES AND METHODS FOR THE PREPARATION AND USE THEREOF | BECKMAN INSTRUMENTS, INC. (US) | 1996-08-14 | — | — | EP | disclosed |
| WO-1996006853-A1 | ACTIVATED NUCLEOSIDE PHOSPHORAMIDITES AND METHODS FOR THE PREPARATION AND USE THEREOF | BECKMAN INSTRUMENTS, INC. (US) | 1996-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156235-A1 | Process for preparing peptide derivatized oligomeric compounds | IAPP, PTMS, NGLY1 | TSHR 3062/4885MAPT 799/4885ALDH1A1 4879/4885 |
| US-20040198972-A1 | Processes for the preparation of oligonucleotides | RNGTT, RNMT, NUDT1 | TSHR 3203/4885MAPT 2388/4885ALDH1A1 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.